Drugs / IT-139
IT-139
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01415297 | Oct 2009 → May 2012 | cancer | Niiki Pharma Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IT-139 | “OBJECTIVE: This phase I clinical study (NCT01415297) evaluated the safety, tolerability, maximum-tolerated dose (MTD), pharmacokinetics and pharmacodynamics of IT-139 (formerly...” PMID 28848672 ↗ Feb 2017 |
| Known as | KP-1339 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297410 ↗ |
| Known as | NKP-1339 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01415297 ↗ |
| Modality | Small molecule | — CHEMBL4297410 ↗ |
| Route | Intravenous | “NKP-1339 is administered as a 30-90 minute IV infusion (based on volume to be infused) on days 1, 8, and 15 of a 28 day cycle.” NCT01415297 ↗ |